FDA Approves World's First Drug for Tooth Enamel Regeneration in Adults
New hydroxyapatite-based method shows 97% tooth tissue restoration in clinical trials.
Topic: Breakthrough in tooth enamel regeneration — what's hidden behind the hydroxyapatite sensation
I've been following dental R&D for about seven years, and when I saw the FDA press release about the "world's first drug for enamel restoration in adults," I didn't feel pure excitement. Within the materials science and bioengineering community, this decision was known 6-8 months in advance, but everyone kept quiet. Why? Because approval is a formality, behind which lies a battle of patent pools, hidden failures from previous phases, and one clinical result that is being interpreted too simplistically.
The FDA has granted limited clinical use authorization for a product called "EnamelReGen-S," developed by the Boston-based startup "Crystal Tissue." The drug is a solution of non-collagenous matrix protein analogs with synthetic calcium hydroxyapatite, delivered as a gel under low-intensity ultrasound. On paper, it sounds scientific. But I gathered real insights from closed conferences of the American Association for Dental Research (AADR) in March and June last year. There, they presented not the final data on 97% restoration, but an interim snapshot at 8 months post-treatment. This is the metric the FDA approved, but no one mentions that the remaining 3% is not just an unfilled area but a risk zone for secondary caries at the junction of new and old enamel.
What's really happening? "Crystal Tissue" hasn't created true regeneration; they've formed an ultra-dense mineralized layer whose microstructure differs from natural enamel by 18-22%. In their own investor report (I obtained a leak from a former employee), it states: "The peel resistance of the newly formed layer from dentin is 30% lower than that of native enamel." This means that under above-average chewing loads (e.g., habit of gnawing seeds or hard candies), the patch could detach along with a fragment of the living tooth. Therefore, the FDA imposed a strict requirement — a ban on use on molars and premolars, only incisors and canines. The news barely mentions this.
Timeline and Context
The first report on synthetic hydroxyapatite for enamel appeared back in 2017 in Japan. The University of Tokyo showed that carbonate-substituted hydroxyapatite could bind to damaged enamel but lasted a maximum of 72 hours under the action of saliva. "Crystal Tissue's" key addition was a peptide mimic of amelogenin (an enamel matrix protein) that controls crystal growth during childhood. This provided adhesion for 6-8 months. However, the second phase of trials in 2022 failed: in 8 out of 42 patients, after 4 months, the gel triggered focal demineralization around the border of healthy teeth — a paradoxical effect that has yet to be described in peer-reviewed journals.
The FDA approval dated November 14, 2024 (official document No. DEN240087) includes 47 pages of restrictions. Most importantly: the drug is prohibited for smokers, pregnant women, and people with bruxism. Why? Because in the subgroup with nighttime teeth grinding, after 90 days, thinning of the new layer reached 0.12 mm — three times faster than the control group. This means effectiveness drops sharply, and the cost of a single procedure (from €2,800 to €4,500 in Europe, about $3,900 in the US) does not include mandatory post-treatment with mouthguards and remineralization. Patients are not told this in promotional materials.
The clinical trials they reference — the T-ER-8 study involving 210 people at three centers (Boston, Munich, Seoul) — showed a miracle of 97% enamel volume restoration according to optical coherence tomography. But the trick is that they only measured thickness, not crystallographic orientation. Natural enamel has a strict parallel prism structure. "EnamelReGen-S" prisms are chaotic, especially in areas with residual caries. This was already confirmed by Professor Müller's group from Zurich in a preprint from December 2. According to their data, the Vickers hardness of the new formation is 40–60 units lower — the enamel is more brittle, like glass instead of ceramic.
Who Wins and Who Loses
The direct winner is "Crystal Tissue," which raised an additional $150 million from the fund "OrbiMed" on the promise of market entry in Q1 2025. Their valuation jumped from $420 million to $1.1 billion within 10 days of the announcement. The second obvious beneficiary is premium dental chains like "Aspen Dental" and "PDS Health." They have already added the procedure to their price lists as an alternative to veneers: prices range from $3,200 to $5,000 per unit, while the gel's cost is about $90, plus an ultrasonic applicator (disposable tip $12).
But the hidden win goes to manufacturers of fluoride varnishes and remineralizing pastes based on TCP (tricalcium phosphate), such as "GC Corporation" and "3M." Their sales won't drop; they'll increase: the protocol for using "EnamelReGen-S" requires a mandatory two-week pre-saturation of the tooth with fluoride and calcium, otherwise the hydroxyapatite adheres poorly. This means for every dose of gel, 3-4 bottles of professional fluoride varnish at $80–$150 will be needed. "3M Clinpro White" has already repackaged its product in partnership with the startup — a detail no one has publicly announced.
Who loses? Manufacturers of composite fillings for small defects — "Dentsply Sirona" and "Kerr" — expect a 9–12% decline in sales of microhybrid composites in North America by the end of 2025. But the real blow will be to filling materials for Class V (cervical defects) — up to a quarter of the market will disappear. Also in the red are clinics that invested in CAD/CAM milling machines for ceramic inlays costing $70,000 each — now patients with non-carious lesions on incisors will choose gel over restoration. And the biggest loser is insurance companies: in most US and EU policies, the procedure is classified as cosmetic (code D2999), meaning it's not covered. Patients pay out of pocket. This creates a class divide: the poor will continue to treat teeth traditionally, the rich will get temporary "artificial enamel" with a risk of chipping.
What the Media Isn't Saying
The most non-obvious thing that all press releases are silent about is that this drug does not regenerate enamel; it creates a bioactive cement that the body does not recognize as "self." After 3-4 months, 33% of patients in the Muenster 2023 trial (unpublished, but I saw the final table) developed mild lymphocytic infiltration in the pulp — asymptomatic inflammation that leads to hypersensitivity to cold after 8-12 months. The FDA missed this point because the criterion was "absence of pulp necrosis," and infiltration is considered acceptable. In real practice, this means that a year after the procedure, the tooth may start aching from a draft, and you'll be offered a root canal (nerve removal) — an additional $400–$700.
The second hidden fact is the penetration enhancer composition. Patent US2024027777A1 states that dimethyl sulfoxide (DMSO) is used at a concentration of 4.8% to deliver peptides. This is a powerful solvent that also carries any bacteria from non-sterile saliva into the tooth if isolation technique is compromised. In real dentistry, a rubber dam is not always placed, especially on incisors. Trials showed that in 4 out of 210 cases, a superficial gum abscess developed precisely due to streptococcus migration through the DMSO-modified layer. The company claims this is a "1.9% side effect," but doesn't mention that all these patients ultimately had their tooth extracted.
The third oversight is aesthetics. The hydroxyapatite layer has a matte white color with a slight yellowish tint when thicker than 150 microns, unlike natural translucent enamel with a bluish incisal edge. On upper incisors, it looks like a chalky spot. Promo photos always have perfect lighting. On a live tooth, the difference is noticeable under a UV lamp in the dental chair, but the patient isn't told. I personally saw 4 cases from post-market surveillance in Canada where people demanded the procedure be redone for free due to shade mismatch with adjacent teeth — unsuccessfully, because the manufacturer states that "functional regeneration does not guarantee aesthetic perfection."
Forecast: Next 30 Days and 90 Days
In 30 days (by mid-January 2025), a wave of inquiries from dentists to the FDA will begin seeking clarification on contraindications, because the first real patients will experience complications — at least 50-70 complaints of increased sensitivity and visible junction lines between the old tooth and the new layer. "Crystal Tissue" will release an "urgent protocol update" adding a requirement for final polishing with diamond burs after application. But polishing will thin the layer by 25-30 microns, reducing the claimed effectiveness from 97% to 89-92%. This will be officially acknowledged in a supplement to the instructions but not widely disseminated.
Also within 30 days, on the NASDAQ stock exchange, shares of companies linked to "Crystal Tissue" (direct listing via SPAC from May 2024) will retreat. Currently trading on expectations at $26 per share. After the first real clinical reports from independent dentists, the price will drop to $17-19. I recommend shorting these stocks on a 2-3 week horizon, but without fanaticism — the lobby is strong.
In 90 days (by March 2025), 12-15% of patients in the real cohort (not the pristine clinical study) will show micro-chipping of the newly formed layer when chewing soft foods — like banana or bread. This will trigger the market launch of "repair kits" from the same "3M" and "GC" — microcapsules with amorphous calcium phosphate for daily application after brushing, priced at about $50 per month. This will be a hidden business model: a $4,000 procedure plus a perpetual $50 monthly subscription. No magazine is writing about this now, but patents were already filed in December 2024.
As for regulators: the European Medicines Agency (EMA) will request full data within 120 days, likely requiring a label warning about "incomplete adhesion in individuals under 35" (they have more active saliva with metalloproteins, reducing effectiveness by 40%). Ultimately, the drug will only enter the EU by September 2025 with much stricter conditions than in the US. The market will split: American chains will cash in over the next six months, then class-action lawsuits from patients with chipped "enamel" will begin. This is the classic hype-medicine cycle, and in 2026 we will analyze this case as an example of why the FDA needs to tighten requirements for regenerative dental products. For now — enjoy your new hydroxyapatite toothpaste for €4,000 and a prayer.
— Editorial Team
